GO
Loading...

Pfizer Inc

More

  • Final Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 6:01 PM ET

    Baxter International Inc. rose$. 78 or 1.1 percent, to $72.76. Bristol-Myers Squibb Co. fell$. 87 or 1.8 percent, to $47.96. Hospira rose$. 79 or 1.9 percent, to $42.93.

  • Most active New York Stock Exchange-traded stocks Monday, 14 Apr 2014 | 2:08 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. Advanced Micro Devices Inc. rose 1.6 percent to $3.71 with 22,506,600 shares traded. Alcoa Inc. rose 2.6 percent to $12.86 with 29,500,100 shares traded.

  • Midday Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 2:08 PM ET

    Baxter International Inc. rose$. 79 or 1.1 percent, to $72.77. Bristol-Myers Squibb Co. fell$. 39 or. 8 percent, to $48.44. Hospira rose $1.35 or 3.2 percent, to $43.49.

  • Early Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 10:21 AM ET

    Baxter International Inc. rose$. 47 or. 7 percent, to $72.45. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.77. Hospira rose$. 10 or. 2 percent, to $42.24.

  • Final Glance: Pharmaceuticals companies Friday, 11 Apr 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $71.98. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $48.83. Hospira fell$. 58 or 1.4 percent, to $42.14.

  • Midday Glance: Pharmaceuticals companies Friday, 11 Apr 2014 | 1:51 PM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $72.41. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $49.36. Hospira fell$. 26 or. 6 percent, to $42.46.

  • Most active New York Stock Exchange-traded stocks Friday, 11 Apr 2014 | 1:51 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AT&T Inc. rose. 2 percent to $35.20 with 34,303,500 shares traded. Alcoa Inc. fell 1.3 percent to $12.54 with 44,879,300 shares traded.

  • April 10- Phibro Animal Health Corp's initial public offering was priced at $15 per share, an underwriter said, below its expected price range of $16- $18 per share. Backed by UK private equity firm 3 i Group Plc, Teaneck, New Jersey- based Phibro is selling 7.352 million shares in the offering.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • Adamas Pharma wavers after IPO raises $48 million Thursday, 10 Apr 2014 | 11:09 AM ET

    NEW YORK— Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million. The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18. The stock rose as much as $1.24, or 7.8 percent, in morning trading but later declined 25 cents to $15.75.

  • Early Glance: Pharmaceuticals companies Thursday, 10 Apr 2014 | 10:24 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $73.08. Bristol-Myers Squibb Co. fell$. 45 or. 9 percent, to $50.12. Hospira fell$. 56 or 1.3 percent, to $43.65.

  • Final Glance: Pharmaceuticals companies Wednesday, 9 Apr 2014 | 6:06 PM ET

    Baxter International Inc. rose $1.15 or 1.6 percent, to $73.45. Bristol-Myers Squibb Co. rose $1.51 or 3.1 percent, to $50.57. Hospira rose$. 69 or 1.6 percent, to $44.21.

  • Most active New York Stock Exchange-traded stocks Wednesday, 9 Apr 2014 | 1:16 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AT&T Inc. fell 1.0 percent to $34.92 with 29,859,800 shares traded. Alcoa Inc. rose 3.8 percent to $13.00 with 47,961,300 shares traded.

  • Midday Glance: Pharmaceuticals companies Wednesday, 9 Apr 2014 | 1:15 PM ET

    Baxter International Inc. rose$. 62 or. 9 percent, to $72.92. Bristol-Myers Squibb Co. rose$. 87 or 1.8 percent, to $49.93. Hospira rose$. 52 or 1.2 percent, to $44.04.

  • *GE tops list, followed by Microsoft, Pfizer, Merck, Apple. WASHINGTON, April 8- Foreign profits held overseas by U.S. corporations to avoid taxes at home nearly doubled from 2008 to 2013 to top $2.1 trillion, said a private research firm's report, prompting a call for reform by the Senate's top tax law writer.

  • Many 'Obamacare' critics accepted its subsidies Tuesday, 8 Apr 2014 | 4:07 PM ET

    Among the corporations is a familiar Democratic nemesis, Koch Industries, the giant conglomerate headed by the billionaire brothers Charles and David Koch. In a Senate chamber speech, Reid noted that Koch Industries benefited from a temporary provision of the health care law.

  • Early Glance: Pharmaceuticals companies Tuesday, 8 Apr 2014 | 10:43 AM ET

    Baxter International Inc. rose$. 24 or. 3 percent, to $72.73. Johnson& Johnson rose$. 04 or percent, to $97.93. Eli Lilly& Co. rose$. 04 or. 1 percent, to $58.66.

  • Final Glance: Pharmaceuticals companies Monday, 7 Apr 2014 | 6:01 PM ET

    Baxter International Inc. fell$. 44 or. 6 percent, to $72.49. Bristol-Myers Squibb Co. rose$. 39 or. 8 percent, to $50.28. Hospira fell$. 37 or. 9 percent, to $43.01.

  • NEW YORK, April 7- Wall Street stocks slumped on Monday, extending a broad retreat in global equities markets from a six-year high touched last week, while U.S. On Wall Street, the biggest decliners were Internet stocks.

  • Alcoa and Pfizer are big market movers Monday, 7 Apr 2014 | 4:37 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Pfizer Inc., down 96 cents to $31.20. BlackRock Inc., down $5.03 to $303.89.

Most Popular Video

Tuesday, 15 Apr 2014 | 6:00 PM ET

Fear and loathing. Mad Money host Jim Cramer looks at fears professional money managers face in the current market environment.

Tuesday, 15 Apr 2014 | 4:00 PM ET

CNBC's Patti Domm sits down with Lindsey Group Chief Market Analyst Peter Boockvar to discuss whether or not inflation could affect the Fed's plans.

Tuesday, 15 Apr 2014 | 3:00 PM ET

CNBC.com Senior Writer John Jannarone talks about what Coca-Cola really needs to do to sustain revenue growth.